I couldn't agree more with your thoughts.
In some ways it would have been beneficial to have a long period of time between the almost certain FDA approval + 2020 market earnings, and the more risky CHF results.
I've considered this too.
If the scenario you outline eventuates, and negative CHF results destroy the initial aGVHD success. Then I'll be so disappointed.
But also be ready to use the opportunity to invest even further, if I believe the SP collapse is completely overblown. ( Which it almost certainly will be).
Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA, page-72
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.055(3.94%) |
Mkt cap ! $1.621B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.45 | $1.40 | $2.622M | 1.842M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 26479 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 393104 | 27 |
View Market Depth
| Last trade - 12.24pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |